Kane Biotech to Unveil revyve Clinical Data at SAWC Fall 2026

Event summary

Kane Biotech will present clinical data on revyve at SAWC Fall 2026 (Oct 15–18, 2026).
Three scientific posters will detail economic impact, compatibility, and tissue oxygenation findings.
Company will showcase revyve product line at Booth #544 and meet with distributors.
revyve Antimicrobial Wound Gel and Spray are FDA 510(k) cleared and Health Canada approved.

The big picture

Kane Biotech's presentation at SAWC Fall 2026 underscores the growing importance of clinical evidence in wound care, particularly for products targeting biofilms. The company's focus on expanding distribution networks aligns with broader industry trends toward specialized treatments for chronic wounds, where biofilm disruption is a key differentiator. Success in this space could position Kane as a notable player in the $20B+ global advanced wound care market.

What we're watching

Clinical Validation: How the presented data will influence clinician adoption of revyve products.
Market Expansion: Whether Kane can secure new distribution partnerships to grow U.S. and international reach.
Regulatory Compliance: The pace at which Kane can maintain and expand its regulatory approvals for revyve products.